查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990125

颈动脉支架市场：依产品类型、材料、输送方式、最终用户和通路划分－2026-2032年全球市场预测

Carotid Stents Market by Product Type, Material, Delivery Mechanism, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，颈动脉支架市场价值将达到 6.59 亿美元，到 2026 年将成长至 6.9471 亿美元，到 2032 年将达到 9.9772 亿美元，复合年增长率为 6.10%。

主要市场统计数据
基准年 2025 6.59亿美元
预计年份：2026年 6.9471亿美元
预测年份 2032 9.9772亿美元
复合年增长率 (%) 6.10%

对颈动脉支架发展历程进行策略性介绍概述，重点在于临床优先事项、影响设备性能的因素以及塑造部署路径的生态系统的力量。

颈动脉支架在介入性心臟病学、血管外科和神经血管保护领域占据着至关重要的地位，其器械创新与不断发展的临床指南和手术最佳实践紧密相关。过去十年，支架设计、材料工程和输送系统的进步重塑了治疗决策过程，降低了手术复杂性，同时提高了器械在解剖结构复杂部位的输送性和适配性。随着医疗服务提供者权衡血管内治疗和外科手术的利弊，相关人员越来越关注器械的具体疗效指标，例如术中卒中预防、长期通畅率以及在弯曲血管中的部署便捷性。

分析当前技术成熟度、实证商业化和营运动态融合在一起，重塑颈动脉支架的采用和竞争格局的现状。

颈动脉支架市场格局正经历着一场变革性的转变，技术、临床和营运等多面向因素的整合正在重新定义竞争优势和医疗服务模式。冶金和表面工程技术的进步提高了支架输送性能，降低了再血管再阻塞的风险；模组化输送系统使得支架即使在以往被认为高风险的解剖结构中也能更稳定地植入。伴随这些技术进步，市场也明显转向以证据为基础的研究，强调真实世界临床註册研究和不同器材间的疗效比较，这反映了相关人员对符合现代临床模式的数据的需求。

重点评估关税波动将如何影响整个颈动脉支架价值链的供应链、采购实务和策略製造决策。

贸易政策趋势和各国政府的关税调整对依赖全球化供应链取得关键零件和成品的医疗设备製造商、经销商和医疗保健系统有着重大影响。关税结构的变化会影响接收成本、库存策略和采购决策，进而影响供应商的定价策略以及与医院和门诊手术中心的合约谈判。跨境采购原料和成品的製造商面临成本规划日益复杂的局面，可能需要调整供应商组合、迁移组装地点或承担额外成本以保持竞争力。

将医疗设备类型、材料科学、输送系统、医疗保健环境和分销模式与临床采用驱动因素和商业性选择连结起来的关键细分资讯。

精细的细分观点揭示了产品特性、材料组成、输送机制、终端用户环境和通路如何相互交织，共同影响临床选择和商业策略。从产品类型来看，球囊扩张型和自扩张式平台之间的差异会影响手术方案的製定、血管粘连行为和病例选择，每种平台在径向力和适应性方面各有优劣。从材质来看，镍钛合金和不銹钢的选择决定了器械的柔软性、抗疲劳性和压缩性能。镍钛合金的超弹性特性使其在弯曲的解剖结构中更受欢迎，而不銹钢可预测的扩张特性则可能在其他类型的病灶中更具优势。从输送机制来看，导丝引导式（OTW）和快速交换式（RE）配置决定了导管的兼容性、交换效率和操作者的偏好，进而影响手术时间和团队工作流程。从终端使用者的角度来看，门诊手术中心和医院等手术环境在病例组成、基础设施需求和报销趋势方面存在差异，这些因素反过来又会影响产品的选择和服务提供。从分销管道的角度来看，直接招标和分销商呈现不同的商业化模式，这会影响价格透明度、合约复杂性和临床服务关係的深度。

从详细的区域观点，将美洲、欧洲、中东、非洲和亚太地区在监管差异、报销现实和医疗保健服务模式方面的细微差别联繫起来。

区域趋势对监管路径、报销框架和医疗服务提供者的偏好有显着影响，这些因素共同决定了颈动脉支架技术的应用和推广。在美洲，成熟的临床网络、完善的註册登记体系和先进的报销流程支持循证医学证据的不断积累，并能够根据手术结果和成本效益实现差异化的产品定位。大规模医疗系统内的卓越中心通常是临床创新和早期应用的枢纽，在将器械改进快速转化为临床实践方面发挥着重要作用。

透过设备创新、证据生成、临床支援和强大的商业运营，实现竞争差异化的策略概述。

颈动脉支架领域的竞争格局日益凸显，其核心在于差异化的器材特性、丰富的实证医学证据以及更优的上市速度。主要企业正致力于研发新一代材料、优化输送系统以及辅助技术，以提升手术安全性和可预测性。与临床研究网络和医疗系统建立策略合作伙伴关係，能够快速收集实证医学证据并检验真实世界疗效，从而增强临床信心并促进产品的迭代改进。

制定可操作的策略重点，以加速临床引入，加强供应链，并使产品开发与报销和程序实际情况相符。

产业领导企业应优先采取一系列具体行动，以提升临床有效性、商业性韧性和营运弹性。首先，透过有针对性的註册研究和可操作的临床研究，加快证据生成，这些研究应关注临床医生优先考虑的终点指标和真实世界表现指标。这些投入能够降低产品推广应用的门槛，并促进产品的迭代改进。其次，透过针对明确定义的临床应用领域（例如针对弯曲的解剖结构或门诊环境下的高效给药方式）客製化设备特性，优化产品系列，从而提升临床相关性和采购吸引力。

对多方面研究途径进行透明的解释，该方法结合了临床医生参与、监管审查和供应链分析，以支持可操作的决策。

本综合报告采用多管齐下的方法，结合与关键相关人员的沟通、有针对性的文献综述和供应链分析，以确保其具有可操作的相关性和方法论的严谨性。报告透过对介入医师、医院采购经理和分销合作伙伴进行结构化访谈，收集定性信息，以获取关于器械性能、手术流程和采购重点的第一手观点。这些实践者的见解与同行评审的临床研究、监管指导文件和器械附加檔进行交叉比对，以检验技术声明并了解法规环境。

简洁地总结了决定颈动脉支架创新和广泛应用长期成功的技术、临床和商业性要求。

总而言之，颈动脉支架领域的特点是技术不断改进、日益重视真实世界临床证据以及商业模式不断演进，这些因素共同影响器械在不同医疗环境中的应用方式。器械创新，尤其是在材料和输送系统方面的创新，提高了手术操作的便利性并扩大了适用范围；同时，证据的累积和监管要求迫使製造商采取更全面的上市后策略。此外，采购和供应链趋势，包括关税因素，也需要积极主动的管理，以确保产品供应的持续性和可预测的服务水准。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 颈动脉支架市场：依产品类型划分

  • 球囊扩张型
  • 自膨胀

第九章：颈动脉支架市场：依材料分类

  • 镍钛诺
  • 不銹钢

第十章：以输送方式分類的颈动脉支架市场

  • 越过电线
  • 快速交换

第十一章 颈动脉支架市场：依最终用户划分

  • 门诊手术中心
  • 医院

第十二章 颈动脉支架市场：依通路划分

  • 在线的
  • 离线

第十三章 颈动脉支架市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 颈动脉支架市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 颈动脉支架市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国颈动脉支架市场

第十七章：中国颈动脉支架市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • B. Braun SE
  • Balton Sp. z oo
  • Becton, Dickinson and Company
  • Biotronik SE & Co KG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Contego Medical, Inc.
  • Cook Group Incorporated
  • InspireMD Inc.
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Silk Road Medical, Inc.
  • Stryker Corporation
  • WL Gore & Associates, Inc.
  • Zhejiang Barty Medical Technology Co., Ltd.
Product Code: MRR-5D693B46C668

The Carotid Stents Market was valued at USD 659.00 million in 2025 and is projected to grow to USD 694.71 million in 2026, with a CAGR of 6.10%, reaching USD 997.72 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 659.00 million
Estimated Year [2026] USD 694.71 million
Forecast Year [2032] USD 997.72 million
CAGR (%) 6.10%

A strategic introduction to carotid stent evolution highlighting clinical priorities, device performance drivers, and the ecosystem forces shaping adoption pathways

Carotid stents occupy a pivotal position at the intersection of interventional cardiology, vascular surgery, and neurovascular protection, with device innovation tightly coupled to evolving clinical guidelines and procedural best practices. Over the past decade, advances in stent design, materials engineering, and delivery systems have reshaped therapeutic decision pathways, reducing procedural complexity while improving device deliverability and conformability in challenging anatomies. As providers balance the trade-offs between endovascular and surgical approaches, stakeholders are increasingly focused on device-specific outcomes such as periprocedural stroke prevention, long-term patency, and ease of deployment in tortuous vessels.

Clinical adoption is driven not only by technical performance but also by the generation of relevant evidence that resonates across multidisciplinary heart and vascular teams. Consequently, companies that demonstrate robust biocompatibility, predictable radial force, and controlled deployment mechanisms gain credibility among interventionalists and proceduralists. Beyond clinical parameters, procedural economics, reimbursement frameworks, and care-site preferences are influencing where and how carotid interventions are performed, prompting vendors to refine product portfolios and support services.

This introduction frames the subsequent analysis by situating carotid stent evolution within a broader healthcare ecosystem, recognizing that adoption pathways are shaped by clinician confidence, regulatory clarity, and the alignment of device attributes with procedural workflows. The remainder of this summary elaborates on transformative shifts, tariff implications, segmentation intelligence, regional dynamics, competitive positioning, and practical recommendations for leaders navigating this complex landscape.

An analysis of converging technological refinements, evidence-focused commercialization, and operational dynamics that are reshaping carotid stent adoption and competition

The carotid stent landscape is undergoing transformative shifts driven by converging technological, clinical, and operational forces that are redefining competitive advantage and care delivery. Advances in metallurgy and surface engineering are enhancing deliverability and reducing restenosis risk, while modular delivery systems are enabling more consistent deployment in anatomies once considered high risk. Parallel to these technical improvements, there is a discernible pivot towards evidence generation that emphasizes real-world registries and comparative device outcomes, reflecting stakeholder demand for data that aligns with contemporary practice patterns.

In addition, payer and provider pressures have elevated the importance of cost-effectiveness and care-site optimization, encouraging manufacturers to engage earlier with health systems to demonstrate workflow efficiencies and value propositions beyond unit price. Innovations in remote proctoring, procedure simulation, and digital procedural support tools are expanding training capacity and lowering the barrier to adoption in centers seeking to scale carotid interventions safely. Regulatory pathways have also evolved, placing greater emphasis on post-market surveillance and iterative device improvements, which in turn incentivizes companies to design robust post-approval evidence plans.

Moreover, supply chain resilience and strategic partnerships have become central to maintaining market continuity, prompting manufacturers to diversify sourcing and streamline distribution models. These combined shifts-technological refinement, evidence-centered commercialization, operational integration, and supply chain pragmatism-are collectively reshaping how products are developed, validated, and adopted across clinical settings, with implications for product roadmaps, commercialization strategies, and cross-functional alignment within organizations.

A focused evaluation of how tariff shifts influence supply chains, procurement behavior, and strategic manufacturing decisions across the carotid stent value chain

Trade policy developments and tariff adjustments enacted by national authorities have material implications for device manufacturers, distributors, and health systems that rely on globalized supply chains for critical components and finished devices. Changes in tariff structures can influence landed cost, inventory strategies, and procurement decision-making, which in turn affects vendor pricing approaches and contract negotiations with hospitals and ambulatory surgical centers. Manufacturers that source materials or finish products across borders face increased complexity in cost planning, and may respond by adjusting supplier mixes, relocating assembly, or absorbing incremental costs to preserve competitiveness.

Beyond immediate cost considerations, tariffs can alter the cadence of product launches and the prioritization of markets for clinical evaluation or commercial expansion. Firms pursuing regional clinical programs or commercial rollouts may re-sequence investments to mitigate exposure to jurisdictions with unfavorable import duties, while maintaining continuity through regional manufacturing or localized partnerships. Additionally, healthcare providers subject to constrained budgets may place greater emphasis on tender processes and long-term supply agreements, incentivizing vendors to offer bundled service packages, risk-sharing arrangements, or value-based contracting mechanisms.

It is also important to consider the indirect effects of tariff shifts on innovation pipelines. Increased production costs or supply-chain disruption can compress R&D budgets and slow iterative improvements for devices that require specialized materials or manufacturing expertise. Conversely, tariff-driven localization efforts can stimulate domestic manufacturing capabilities, creating opportunities for regional suppliers and potentially shortening response times for clinical support and custom configurations. In sum, tariff movements necessitate strategic recalibration across procurement, manufacturing, and commercial functions to sustain product availability and preserve competitive positioning.

Critical segmentation intelligence linking device type, material science, delivery systems, care settings, and distribution models to clinical adoption drivers and commercial choices

A nuanced segmentation lens reveals how product characteristics, material composition, delivery mechanics, end-user environments, and distribution pathways collectively shape clinical selection and commercial strategy. Based on Product Type, the distinction between Balloon-Expandable and Self-Expanding platforms influences procedural planning, vessel apposition behavior, and case selection, with each platform offering differential trade-offs in radial force and conformability. Based on Material, choices between Nitinol and Stainless Steel underpin device flexibility, fatigue resistance, and crimping dynamics; Nitinol's superelastic properties are frequently preferred in tortuous anatomies, whereas Stainless Steel's predictable expansion profiles can be advantageous in other lesion subsets. Based on Delivery Mechanism, Over The Wire and Rapid Exchange configurations determine catheter compatibility, exchange efficiency, and operator preference, with implications for procedure time and team workflow. Based on End User, procedural settings such as Ambulatory Surgical Centers and Hospitals diverge in case mix, infrastructure requirements, and reimbursement dynamics, which in turn affect product selection and service offerings. Based on Distribution Channel, Direct Tender and Distributors present different commercialization models, influencing pricing transparency, contract complexity, and the depth of clinical-service relationships.

Understanding this segmentation matrix enables stakeholders to align product development priorities with clinician needs and care-site constraints. For example, a device optimized for rapid exchange may be more attractive to high-throughput ambulatory centers seeking reduced procedure times, whereas a stent engineered with specific material properties may address anatomical challenges encountered in tertiary vascular centers. Similarly, distribution decisions-whether to engage through direct tendering or partner with established distributors-should be informed by the target end-user mix and the desired level of post-sale clinical support. Ultimately, a segmentation-aware approach ensures that product features, commercial models, and deployment strategies are coherently matched to the diverse environments in which carotid interventions are performed.

In-depth regional perspectives that connect regulatory nuance, reimbursement realities, and care delivery models across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on regulatory pathways, reimbursement frameworks, and provider preferences, which together determine how carotid stent technologies are introduced and scaled. In the Americas, established clinical networks, robust registry infrastructures, and progressive reimbursement pathways support iterative evidence generation and allow for differentiated product positioning based on procedural outcomes and cost-effectiveness considerations. Centers of excellence within large health systems often serve as hubs for clinical innovation and early adoption, which accelerates the translation of device enhancements into practice.

In Europe, Middle East & Africa, heterogeneous regulatory environments and diverse healthcare funding models require adaptable market entry strategies that account for variable procurement cycles, national device approvals, and differing clinical practice patterns. Collaboration with regional clinical leaders and alignment with local reimbursement authorities are essential for gaining traction across this geographically and economically diverse region. Local partnerships and targeted evidence generation can help bridge variability and support scaled adoption in both advanced and emerging healthcare markets.

In Asia-Pacific, rapidly expanding procedural volumes, investments in interventional capacity, and an increasing emphasis on domestic manufacturing are reshaping competitive dynamics. Regional centers are embracing new device classes while simultaneously cultivating localized supply chains and clinical data collection. Market entrants should anticipate a blend of centralized high-volume referral centers and decentralized community hospitals, adapting commercial and training models accordingly. Across all regions, clinicians and procurement teams are placing increasing weight on real-world evidence, training support, and supply reliability, making regionalized strategies and operational flexibility central to sustained success.

A strategic overview of competitive differentiation through device innovation, evidence generation, clinical support, and resilient commercial operations

Competitive positioning in the carotid stent arena increasingly revolves around differentiated device attributes, evidence portfolios, and go-to-market excellence. Leading companies are investing in next-generation materials, optimized delivery systems, and adjunctive technologies that enhance procedural safety and predictability. Strategic alliances with clinical research networks and health systems are enabling expedited evidence collection and real-world performance validation, which strengthens clinical credibility and informs iterative product refinement.

Commercial differentiation is further achieved through comprehensive service offerings, including training programs, procedure simulation, and peri-procedural support designed to de-risk adoption for new users. Firms that can demonstrate rapid clinical onboarding and measurable procedural efficiency gains are more successful in securing long-term procurement agreements with hospitals and ambulatory centers. Additionally, organizations that integrate supply chain resilience into their value proposition-offering reliable lead times, multiple sourcing options, and responsive field support-are better positioned to withstand operational disruptions.

From a product portfolio perspective, companies that maintain a balanced pipeline-covering traditional stent platforms and adjunctive devices such as embolic protection systems-are better able to tailor combined solutions that align with physician preferences. Furthermore, innovative pricing and contracting approaches, including value-based arrangements and volume guarantees, are being used selectively to build durable customer relationships. In summary, competitive advantage is built at the intersection of superior device engineering, sustained clinical evidence, and differentiated commercial capabilities that together reduce adoption friction and elevate clinician confidence.

Actionable strategic priorities to accelerate clinical adoption, fortify supply chains, and align product development with reimbursement and procedural realities

Industry leaders should prioritize a set of concrete actions to strengthen clinical relevance, commercial resilience, and operational agility. First, accelerate evidence generation through targeted registries and pragmatic clinical studies that address clinician-prioritized endpoints and real-world performance metrics; these investments reduce adoption barriers and inform iterative product improvements. Second, optimize product portfolios by aligning device attributes to clearly defined clinical niches-such as tortuous anatomy solutions or streamlined delivery for ambulatory settings-to increase clinical relevance and procurement appeal.

Third, strengthen supply chain resilience by diversifying component sourcing and exploring regional assembly to mitigate tariff exposure and shorten replenishment cycles. This may include strategic partnerships with local manufacturers and the deployment of dual-sourcing strategies for critical materials. Fourth, enhance commercial engagement models by offering training, proctoring, and procedural simulation that reduce operator learning curves and demonstrate tangible workflow efficiencies. Fifth, expand strategic contracting options to include outcome-linked agreements and bundled service packages that align incentives with institutional priorities and procurement frameworks.

Finally, invest in cross-functional alignment between R&D, regulatory, and commercial teams to ensure that product development plans incorporate regulatory realities, reimbursement considerations, and clinician feedback early in the lifecycle. By implementing these actions, organizations can better navigate policy shifts, clinician expectations, and competitive pressures while delivering solutions that meaningfully improve procedural outcomes and operational performance.

A transparent description of the multi-method research approach combining clinician engagement, regulatory review, and supply-chain analysis to support pragmatic decision-making

This research synthesis integrates a multi-method approach combining primary stakeholder engagement, targeted literature review, and supply-chain analysis to ensure pragmatic relevance and methodological rigor. Qualitative inputs were obtained through structured interviews with interventional clinicians, hospital procurement leaders, and distribution partners to capture firsthand perspectives on device performance, procedural workflow, and purchasing priorities. These practitioner insights were triangulated with peer-reviewed clinical studies, regulatory guidance documents, and device labeling to validate technical claims and understand the regulatory environment.

Operational and commercial analyses incorporated supply-chain mapping, tender dynamics assessments, and distribution channel evaluation to surface potential vulnerabilities and opportunities for localization or partnership. Expert validation sessions with clinical and industry advisors were used to refine key assumptions and ensure that conclusions reflect contemporary practice and device capabilities. Throughout the analysis, care was taken to distinguish empirical clinical evidence from strategic implications, and to present implications in a manner that supports applied decision-making.

Limitations of the methodology are acknowledged, including variability in regional data availability and the inherent lag between clinical practice evolution and published literature. Where appropriate, the analysis leans on clinician-provided real-world observations to supplement formal publications, and emphasizes transparent sourcing of technical and regulatory inputs. The methodology thus balances empirical grounding with practical insight to deliver a resource that informs clinical, operational, and commercial strategy.

A concise conclusion synthesizing technological, clinical, and commercial imperatives that determine long-term success in carotid stent innovation and adoption

In summary, the carotid stent domain is characterized by ongoing technological refinement, heightened emphasis on real-world evidence, and evolving commercial models that together shape how devices are adopted across diverse care settings. Device innovation-particularly in materials and delivery systems-is translating into improved procedural ease and expanded applicability, while evidence generation and regulatory requirements are driving manufacturers to adopt more comprehensive post-market strategies. At the same time, procurement and supply-chain dynamics, including tariff considerations, require proactive management to ensure continuous product availability and predictable service levels.

Organizations that successfully align engineering innovation with targeted clinical validation, resilient manufacturing strategies, and flexible commercial models will be better positioned to meet clinician needs and institutional priorities. Strategic investments in training infrastructure, local partnerships, and evidence generation can accelerate clinician confidence and reduce adoption friction. Equally important is the need for cross-functional collaboration within companies to ensure that product development, regulatory planning, and commercialization are mutually reinforcing.

Overall, the landscape presents significant opportunities for companies that combine technical excellence with disciplined execution across evidence generation, supply chain design, and customer engagement. By heeding these combined imperatives, leaders can convert insight into measurable improvements in patient care pathways and sustainable commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Carotid Stents Market, by Product Type

  • 8.1. Balloon-Expandable
  • 8.2. Self-Expanding

9. Carotid Stents Market, by Material

  • 9.1. Nitinol
  • 9.2. Stainless Steel

10. Carotid Stents Market, by Delivery Mechanism

  • 10.1. Over The Wire
  • 10.2. Rapid Exchange

11. Carotid Stents Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals

12. Carotid Stents Market, by Distribution Channel

  • 12.1. Online
  • 12.2. Offline

13. Carotid Stents Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Carotid Stents Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Carotid Stents Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Carotid Stents Market

17. China Carotid Stents Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. B. Braun SE
  • 18.7. Balton Sp. z o. o.
  • 18.8. Becton, Dickinson and Company
  • 18.9. Biotronik SE & Co KG
  • 18.10. Boston Scientific Corporation
  • 18.11. Cardinal Health, Inc.
  • 18.12. Contego Medical, Inc.
  • 18.13. Cook Group Incorporated
  • 18.14. InspireMD Inc.
  • 18.15. Medtronic PLC
  • 18.16. MicroPort Scientific Corporation
  • 18.17. Silk Road Medical, Inc.
  • 18.18. Stryker Corporation
  • 18.19. W. L. Gore & Associates, Inc.
  • 18.20. Zhejiang Barty Medical Technology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CAROTID STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CAROTID STENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CAROTID STENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CAROTID STENTS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CAROTID STENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CAROTID STENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CAROTID STENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CAROTID STENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CAROTID STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CAROTID STENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CAROTID STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CAROTID STENTS MARKET SIZE, BY BALLOON-EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CAROTID STENTS MARKET SIZE, BY BALLOON-EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAROTID STENTS MARKET SIZE, BY BALLOON-EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAROTID STENTS MARKET SIZE, BY SELF-EXPANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAROTID STENTS MARKET SIZE, BY SELF-EXPANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAROTID STENTS MARKET SIZE, BY SELF-EXPANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CAROTID STENTS MARKET SIZE, BY NITINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CAROTID STENTS MARKET SIZE, BY NITINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CAROTID STENTS MARKET SIZE, BY NITINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CAROTID STENTS MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CAROTID STENTS MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CAROTID STENTS MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CAROTID STENTS MARKET SIZE, BY OVER THE WIRE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CAROTID STENTS MARKET SIZE, BY OVER THE WIRE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAROTID STENTS MARKET SIZE, BY OVER THE WIRE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAROTID STENTS MARKET SIZE, BY RAPID EXCHANGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAROTID STENTS MARKET SIZE, BY RAPID EXCHANGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CAROTID STENTS MARKET SIZE, BY RAPID EXCHANGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CAROTID STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CAROTID STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CAROTID STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CAROTID STENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CAROTID STENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CAROTID STENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAROTID STENTS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAROTID STENTS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAROTID STENTS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CAROTID STENTS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CAROTID STENTS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CAROTID STENTS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CAROTID STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS CAROTID STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CAROTID STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CAROTID STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASEAN CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. GCC CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GCC CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. GCC CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 96. GCC CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 97. GCC CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GCC CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPEAN UNION CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. G7 CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. G7 CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. G7 CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 114. G7 CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 115. G7 CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. G7 CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. NATO CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NATO CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NATO CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. NATO CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 121. NATO CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. NATO CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CAROTID STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES CAROTID STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. UNITED STATES CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA CAROTID STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. CHINA CAROTID STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. CHINA CAROTID STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA CAROTID STENTS MARKET SIZE, BY DELIVERY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 134. CHINA CAROTID STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. CHINA CAROTID STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)